Search This Blog

Monday, August 31, 2026

'Araghchi says US launched attacks from UAE territory'

 

Iranian Foreign Minister Abbas Araghchi said in an interview with MS NOW’s Velshi that US forces used locations in the United Arab Emirates to launch rocket attacks on Iran’s Kharg and Abu Musa islands.

“The reaction would be clear,” Araghchi said. “Last night they attacked Kharg Island and Abu Musa Island” using HIMARS rockets.

He said Iranian forces tracked the launches and determined they came from two locations in the UAE, including Ras Al-Khaimah and an area near Dubai.

“It is now clear that they were fired from the UAE,” Araghchi said, calling the use of neighboring territory to attack Iran “absolutely unacceptable.”

He also said it was “very dangerous” to launch rockets from areas close to heavily populated locations.

https://www.iranintl.com/en/202609011321

Jefferies starts biopharma firm Braveheart at Buy after IPO

 Jefferies initiated coverage of Braveheart Bio with a Buy rating and a $48 price target, implying roughly 75% upside from the stock's prior closing price. The move comes after the company priced its initial public offering (IPO) at $18 per share earlier this month, raising $382.5 million in one of the largest biotech debuts of 2026.

The clinical-stage biotech is developing BHB-1893, an oral cardiac myosin inhibitor licensed from China-based Hengrui in September 2025, for hypertrophic cardiomyopathy (HCM), a progressive heart disorder affecting more than 700,000 U.S. patients.

Jefferies analysts led by Andrew Tsai said the drug "could offer superior attributes" compared with existing treatments, including Bristol Myers Squibb's Camzyos and Cytokinetics' Myqorzo.

The analysts highlighted Phase II data from Hengrui showing BHB-1893 achieved a 76% reduction in a key obstruction measure by week 12, with 86% of patients reaching normalized heart flow, "better than 49-57% in BMY/CYTK's Phase IIIs after Week 24." None of the responders showed clinically significant reductions in heart pump function, described in the note as having "no LVEF cost."

Jefferies said BHB-1893's global Phase III study in obstructive HCM, called LIONHEART-HCM, is expected to begin in the second half of 2026, with interim data due in the second half of 2027.

A separate Hengrui-led Phase III study in China is expected to report topline data in the first half of 2027. The company is pursuing an accelerated path toward a new drug application filing as early as year-end 2027.

For non-obstructive HCM, analysts said the drug "could be a best-in-class asset, justifying $2-3B in sales." A Phase III study called NOBLEHEART-HCM is set to begin in the first half of 2027, with data expected in the second half of 2029.

Jefferies' $48 price target is based on a sum-of-the-parts discounted cash flow analysis, assigning $15 per share to the obstructive HCM opportunity based on $1.5-2 billion in peak sales and a 20%-30% probability of success, $27 per share to non-obstructive HCM based on $2-3 billion in sales and a 25%-35% probability of success, and $4 per share to a heart failure indication based on $1 billion-plus in sales and a 10% probability of success.

The bank's upside scenario points to $125 per share, while its downside case sits at $6. Jefferies flagged competition, clinical trial translation between Phase II and Phase III, differences between Asian and non-Asian patient populations, and regulatory risk as key considerations for the stock.

https://finance.yahoo.com/healthcare/articles/jefferies-starts-biopharma-firm-braveheart-110019166.html

Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis

 

Biomarin has granted Ascendis a non-exclusive, worldwide license to use navepegritide, the active ingredient in the latter company’s recently approved achondroplasia drug Yuviwel, in exchange for 18–20% royalties on net sales.

Biomarin and Ascendis Pharma have settled a legal battle over the patents for the companies’ rival achondroplasia drugs. Analysts heralded the agreement as a win for Biomarin, which scored a higher-than-expected royalty rate on sales of Ascendis’ Yuviwel.

At issue is the European patent for Biomarin’s Voxzogo. The company argued in its January 2025 complaint that Ascendis’ therapy, which at the time was under development as TransCon CNP, infringed on the patent for Voxzogo. The patent that had been awarded for Voxzogo covered long-acting variants of C-type natriuretic peptide (CNP).

TransCon CNP, which was approved in February as Yuviwel, is a pro-drug version of CNP that is designed to increase exposure of the active ingredient and improve efficacy and safety.

The case eventually came to center on legal hang ups around Ascendis’ attempt to delay hearing the case while Yuviwel was under review by the FDA. The court ruled against Ascendis in March, shortly after it secured approval for Yuviwel in February.

But the underlying patent issues had yet to be resolved. Now, the two sides have come to an agreement, according to separate press releases issued Monday by the companies.

Biomarin has granted Ascendis a non-exclusive, worldwide license to use Yuviwel’s active ingredient, which is called navepegritide, in achondroplasia, hypochondroplasia and other indications.

“We view the agreement as a win-win for Ascendis and BioMarin,” BMO Capital Markets wrote in a Monday morning note.

Ascendis will pay 18–20% royalties on net sales to Biomarin, depending on where the drug is sold, through May 20, 2030.

“The royalty rates appear relatively high compared with recent biotech patent settlements, while the duration is relatively short,” BMO said.

In a separate note to investors, Stifel said a settlement had been expected but not the high royalty rate. “For legal cases there’s never really a perfect precedent or analog, but a high-teens/20% royalty is at the high end of these types of agreements,” the firm said.

Analysts believe the timeline matches up with Biomarin’s plan to launch the investigational BMN 333 as a once-weekly, long-acting CNP option for the diseases.

Ascendis can now move forward unimpeded with Yuviwel, a drug that BMO believes has wide potential “to lead the achondroplasia and broader CNP market.”

“The ongoing rapid uptake of Yuviwel in the United States, we believe, reflects its differentiated profile and the large, unmet medical need it is addressing as an important new foundation of care in achondroplasia and other types of skeletal dysplasia,” said Jan Møller Mikkelsen, CEO of Ascendis, in a Monday statement.

Biomarin, on the other hand, is facing a loss of market share for Voxzogo but will now get a nice chunk of change from its rival out of the settlement.

“For BioMarin, the high royalties provide meaningful participation in Yuviwel’s growth and should partially offset expected Voxzogo erosion as the weekly competitor gains adoption,” BMO said. Now, Biomarin can focus on BMN 333, the firm continued.

Stifel said that the agreement “signifies confidence” in potential next-gen drug BMN 333. Preliminary data from a Phase 3 trial of the asset is due in 2027.

“This outcome incentivizes companies like BioMarin to keep investing in the kind of long-term innovation that is critical to bringing breakthrough treatments to the people who need them,” said Alexander Hardy, CEO of BioMarin, in a prepared statement.

https://www.biospace.com/business/biomarin-nabs-big-royalties-in-achondroplasia-patent-settlement-with-ascendis

White House unveils next round of MFN pricing deals with 9 midsized drugmakers

 Some four months after the White House inked the last of its expected drug pricing deals with 17 of the industry’s top players, the U.S. government is back for round 2, this time lining up agreements with a host of medium-sized biopharmas under President Trump’s ‘most favored nation’ agenda. 

Up at the dealmaking table for this round are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB, according to a White House fact sheet issued Monday afternoon. 

Notably, the new list includes companies from further afield than Europe and the U.S.—which dominated the first 17 MFN accords struck from last year through late April of 2026—with Sun based in India, Teva hailing from Israel, and Astellas and Kyowa Kirin headquartered in Japan, not to mention CSL in Australia. 

Details are mostly thin on which of the companies’ specific drugs are included in the pricing agreements and the precise discounts in the offing.

The President’s MFN drug pricing campaign has broadly sought to realign prescription costs in the U.S. based on what certain high-income comparator countries pay. Specifically, the administration has worked toward MFN prices by utilizing net prices paid in Canada, Denmark, France, Germany, Italy, Japan, Switzerland and the U.K.

While the administration has made big claims about the scope of savings its pricing measures could deliver, the fine details of the previous government-industry deals remain murky, with their true impact on medicine affordability for U.S. patients a continuing topic of debate. 

As with previous MFN deals, the midsized drugmakers lining up to sign have made financial commitments to their U.S. operations, too, boasting a collective investment pledge of at least $19.6 billion in American production in the near term, according to the fact sheet. 

Several of the firms have also agreed to donate active pharmaceutical ingredients (APIs) for certain products to the U.S.’ Strategy Active Pharmaceutical Ingredients Reserve (SAPIR), which the White House says will help curb reliance on foreign suppliers and bolster supplies in the event of a potential emergency. 

While many companies have agreed to onshore or expand certain portions of their manufacturing processes to the U.S. in recent years, the fundamental step of producing drug ingredients remains largely concentrated overseas in countries like China and India. 

Belgium’s UCB has agreed to contribute 163 tons of API for the seizure drug levetiracetam, while Sun will throw in 71.4 tons and 6.75 tons of the antibiotics clindamycin and doxycycline, respectively. 

For its part, Teva is pitching in 45 tons of the antibiotic metronidazole and 4.8 tons of the hypertensive drug amlodipine, while Astellas is adding 25 kg of the immunosuppressant tacrolimus to the SAPIR. 

While the White House release did not allude to tariffs on Monday, the cudgel of trade duties has been ever present in the deals struck so far.  

In the first round of agreements, of which Regeneron was the last to sign on in April, Big Pharma companies from Pfizer and AstraZeneca to Roche, Novartis and Johnson & Johnson made a combination of drug pricing commitments and domestic investment pledges to win temporary immunity from the Trump administration’s drug import tariffs. Midsized companies were not involved in the first round of dealmaking. 

Individual company press releases Monday, like UCB’s, suggest that tariff immunity is still very much part of the MFN equation. 

Oncology specialist BeOne also said it locked down an exemption from Section 232 pharmaceutical tariffs because of its investments in U.S. manufacturing. The company leaned on its participation in GENEROUS, an industry-government negotiation framework laid out early this year under which manufacturers provide rebates to participating states for certain drugs. Although the company sells multiple products in the U.S., currently only PD-1 inhibitor Tevimbra is subject to the Medicaid program.

Meanwhile, BridgeBio will also expand state Medicaid access to Attruby under the GENEROUS model. The drug for transthyretin amyloid cardiomyopathy is the California company’s only commercial brand. Thanks to the new agreement, the company said Monday that it “does not expect to be subject to future pricing mandates.”

Reporting $502.1 million in full year revenues in 2025, BridgeBio is notably smaller than many of the other “mid-sized” pharmas who have lined up for this second round of deals.

CSL, for its part, tied the agreement with the government to a recently disclosed plan for a $1.5 billion manufacturing plant expansion near Chicago.

The company specified that under the deal, it will provide Medicaid access to its drugs at prices on par with other developed countries, alongside a pledge to similarly price any new therapies for all payers in the U.S.

“These agreements provide a sustainable and stable access framework to important medicines for people living with rare diseases and serious conditions while strengthening the manufacturing capabilities, supply infrastructure and scientific innovation required to deliver those therapies reliably,” Diego Sacristan, CSL’s commercial chief, said in a statement. 

Recognizing the lack of similarly positioned firms at the table, 10 U.S. biotechs forged the Midsized Biotech Alliance of America (MBAA) back in February, taking aim at Trump’s MFN policy writ large. 

The group, whose original lineup included Alkermes, Alnylam, Ardelyx, BioMarin, Exelixis, Incyte and Neurocrine Biosciences, argued at the time that midsized companies are less well-positioned to weather MFN than resource-stocked Big Pharma, given that they’re often reliant on a single marketed product targeting more niche patient needs. 

https://www.fiercepharma.com/pharma/white-house-unveils-next-round-mfn-pricing-deals-9-midsized-drugmakers

China-Linked Activist Network Preparing To Activate Against Carney's Rare-Earths Push

 by The Bureau's Sam Cooper (emphasis our own),

The Ring of Fire sits about 500 kilometers northeast of Thunder Bay in the muskeg of Ontario’s James Bay Lowlands, on Treaty 9 territory. Prospectors found it in 2007 and named it after a Johnny Cash song.

Beneath the peat moss lies the Canadian Shield, deeply seamed with nickel and cobalt for batteries used in electric vehicles and smart phones, copper for the grids that power data centers, titanium, platinum and palladium for aerospace, and the largest deposit of chromite — critical to stainless steel — in North America.

Nine Cree and Ojibwa communities live in and around it.

On September 14, Prime Minister Mark Carney opens the Canada Investment Summit in Toronto, where he is expected to pitch the Ring of Fire as Canada’s answer to a new world in which access to critical minerals has become an instrument of great-power leverage.

A coalition that advertises itself as anti-capitalist will be in Toronto too.

One of its three conveners has direct organizational ties to CODEPINK, the American anti-war group now under investigation in Washington and London.

The Indigenous and eco-justice coalition says it brings together labor unions and climate networks, and opposes “the sell-off of Canada’s public infrastructure and resources to global private capital.” From September 12 to 14, it will hold a counter-summit, “culminating in a mass rally and demonstration to crash Mark Carney’s Investment Summit.”

Of the conveners, World BEYOND War has the deepest international connections. Headquartered in the United States, it obtained its own charitable status in September 2021 after years under a fiscal sponsor. CODEPINK co-founder Medea Benjamin sits on its advisory board.

Whether interests from Beijing sit behind CODEPINK’s funding is now a question for two Five Eyes governments. No such allegation has been made about any organization in the Ring of Fire coalition.

The Telegraph reported in August that Britain’s Home Office was examining claims that Beijing was funding pro-Palestinian protests to “sow division and chaos” in Britain.

The paper also reported that a British company linked to CODEPINK allegedly received about £250,000 from businesses connected to Neville Roy Singham, a China-based technology millionaire accused of financing Chinese propaganda.

Singham has consistently denied allegations of Beijing backing.

Yet footage from a November 2025 academic forum in Shanghai, co-sponsored by Singham with East China Normal University, showed him standing with attendees, fists raised, as the communist anthem “The Internationale” played. He is married to Jodie Evans, CODEPINK’s other co-founder.

In Washington, a congressional committee and the Justice Department are running parallel inquiries into whether Singham used his money to spread pro-China propaganda and advance the interests of Beijing.

The New York Times documented in 2023 that entities linked to Singham had supplied more than $1.4 million to CODEPINK — close to a quarter of its donations since 2017. The Times’ investigation, cited since in congressional letters and at a February 2026 Ways and Means hearing on foreign influence in American nonprofits, opened not on the Middle East causes the Telegraph raised this year but on a street fight in London.

“The protest in London’s bustling Chinatown brought together a variety of activist groups to oppose a rise in anti-Asian hate crimes. So it was peculiar when a street brawl broke out among mostly ethnic Chinese demonstrators,” the Times reported. The fight, in November 2021, “started when men aligned with the event’s organizers, including a group called No Cold War, attacked activists supporting the democracy movement in Hong Kong.”

“On the surface, No Cold War is a loose collective run mostly by American and British activists who say the West’s rhetoric against China has distracted from issues like climate change and racial injustice,” the paper reported.

“In fact, a New York Times investigation found, it is part of a lavishly funded influence campaign that defends China and pushes its propaganda. At the center is a charismatic American millionaire, Neville Roy Singham, who is known as a socialist benefactor of far-left causes.”

Mr. Singham, the Times added, “works closely with the Chinese government media machine and is financing its propaganda worldwide.”

CODEPINK co-founder Medea Benjamin’s connection to World BEYOND War is financial as well as advisory.

Her family foundation, Arc of Justice, reported a $100,000 grant to World BEYOND War in its 2022 federal tax filing, recorded as general support. The same filing lists $355,350 to CODEPINK.

The two organizations also share an institutional funder, the Tides Foundation, a large American grantmaker. World BEYOND War names Tides among its foundation supporters; Tides reported grants of $104,500 to CODEPINK in 2022 and $54,500 in 2023.

In March, CODEPINK helped organize what it called a humanitarian convoy to Cuba with The People’s Forum, one of the New York groups the Times identified as funded by Singham. Medea Benjamin, whose CODEPINK had received more than $1.4 million from Singham-linked entities, joined the trip, along with political streamer Hasan Piker. The Treasury Department opened an administrative review. Benjamin called it intimidation and denied reports that she had been subpoenaed.

In March 2025, World BEYOND War joined an anti-mining protest in Toronto — at the world’s largest mining gathering — alongside the Palestinian Youth Movement, the Sudanese Solidarity Collective, and Canadian indigenous groups.

The demonstrators denounced what they called conflict minerals and green militarism, naming cobalt, coltan, antimony, rare earths, niobium and thorium. “Every F-35 fighter jet has about 900 pounds of rare earths in it,” one argument ran. “Those weapons are being used to bomb civilians in Gaza.”

Another held that “Canadian companies can dig up critical minerals used to make the bombs that are bombing other Indigenous people, on their lands, around the world.”

On January 21, 2026, World BEYOND War published on its own site an essay by CODEPINK’s “War Is Not Green” campaigner, arguing that artificial intelligence data centers are an engine of militarized extraction, relying on critical minerals.

“The process of obtaining these minerals ... requires the militarization, destabilization, and total plunder of mineral-rich regions.”

The question of whether foreign money moves through Western environmental coalitions was put to Brenda Shaffer at a Hudson Institute panel in Washington on May 19, convened by former U.S. national security official Michael Doran with research fellow Zineb Riboua and this reporter. Shaffer teaches at the United States Naval Postgraduate School’s Energy Academic Group.

She was asked about Tides — which World BEYOND War lists among its funders — and called it “an American based organization” that is “strongly affiliated with democratic causes in the US.”

“Many, many organizations and American organizations work as pass throughs for China to block energy in Canada, but also to block energy in the United States,” Shaffer said. “For instance, there’s Energy Foundation, which is based in San Francisco, which used to be a legally explicit Chinese organization, but it broke off to an American organization and a Chinese organization.”

You see the 990 forms and you see money comes in from China to Energy Foundation,” she said. “Money goes from Energy Foundation into various environmental movements in the United States that are working against fossil fuels. And if China was really so interested about stopping fossil fuels, you would think they, the largest consumer of coal in the world, the largest producer, they would stop it at home.”

On December 16, 2025, 26 state attorneys general asked Attorney General Pamela Bondi to investigate Energy Foundation China under the Foreign Agents Registration Act, alleging it “is supervised by the National Development and Reform Commission — an arm of the Chinese government” and is led by Beijing-based former Chinese Communist Party officials. Its chief executive, Ji Zou, previously served as a deputy director general of China’s National Center for Climate Change Strategy. The letter says that “in 2023 alone it gave over $156 million in grants to environmental and climate-focused groups.”

A search of the Tides Foundation’s amended 2022 Form 990 shows that it reported $16,292,728 in grant-making expenditures and investments in East Asia and the Pacific. The filing itemizes 157 grants of more than $5,000 to recipients in that region.

Because the public-disclosure form leaves foreign recipients’ names and employer identification numbers blank, it cannot be determined from this filing whether Energy Foundation China or any other particular entity received those funds.

The public filing also does not identify Tides’ contributors, so it cannot establish whether Tides received funds from Asia.

https://www.zerohedge.com/commodities/china-linked-activist-network-preparing-activate-against-carneys-rare-earths-push

Chinese Scientists Flagged Glacial Flood Danger One Year Before Nepal Catastrophe

 by Sophia Lam via The Epoch Times,

More than a year before the catastrophic flash flood devastated the China-Nepal border crossing at Gyirong last week, Chinese geologists had raised concerns about the impending danger.

CCTV footage shows people running away as wall of mud and water destroys buildings in a valley at the Nepal-China border, in Gyirong, Tibet region, China, on Aug. 26, 2026. Social Media/via Reuters

On August 26, a glacial-related collapse tore through Gyirong Port, one of the principal land crossings between Tibet and Nepal, destroying roads and bridges and leaving entire communities isolated and struggling to reach survivors. Villages and communities along the border have been left in ruins, with homes, roads, and infrastructure swept away.

At least 789 people have died, and more than 3,000 people are still missing.

More than a year ago, on July 8, 2025, a glacial lake outburst flood struck Gyirong County, in Shigatse, Tibet - the same area hit by the recent flash flood - destroying the Friendship Bridge on the China-Nepal border and leaving 17 people missing, according to the state-run Xinhua News Agency.

Chinese scientists at the State Key Laboratory of Geohazard Prevention and Geoenvironment Protection at Chengdu University of Technology published a study three days after the 2025 flood, warning that the area could experience another glacial lake outburst flood in the wake of the July 8 disaster.

They called for stronger upstream flood warnings and recommended conducting detailed assessments of the susceptibility and risks of all glacial lakes in the basin "as soon as possible" to support "post-disaster reconstruction and long-term stability."

A Warning Ignored

Drawing on their Qinghai-Tibet Plateau glacial lake database and risk assessments, these scientists identified 55 glacial lakes covering about 3.39 square kilometers [36 million square feet] in the watershed upstream basin of the Friendship Bridge.

Based on satellite imagery from July 8, the researchers determined that the flood was triggered by the outburst of a supraglacial lake upstream of the Purepu Zangbu River. The report found that the lake had also experienced an outburst in mid-July 2023.

According to the study, the lake began forming in 2018 and is a typical seasonal supraglacial lake rather than a permanent one.

Researchers said rising temperatures across the Qinghai-Tibet Plateau have intensified meltwater runoff and accelerated glacier melt, causing the lake to reach its largest recorded area.

Meltwater carrying large amounts of glacial debris may also have blocked subglacial drainage channels, preventing the lake from draining effectively. The water level eventually rose beyond historical extremes, triggering the July 8, 2025, outburst.

Chinese land on the left and Nepalese land on right after Friendship bridge, a key bridge over the Bhotekoshi River connecting Nepal with China, was swept away in monsoon rain at Rasuwagadi, 120 kilometers (75 miles) north of the capital, Kathmandu, Nepal, on July, 9, 2025. AP Photo/Sujan Gurung

The researchers warned of "the possibility of another glacial lake outburst flood" due to the "many glacial lakes in this river basin."

They also called for "strengthened" upstream early flood warning systems and more detailed hazard and "susceptibility and risk" assessments for all 55 lakes "as soon as possible."

Xu Qiang, president of Chengdu University of Technology, repeated the findings from the 2025 report to explain the recent flood in an interview with the Chinese Communist Party's (CCP's) propaganda outlet People's Daily.

"Against the backdrop of climate warming, the risk of glacial lake outburst floods and debris flows triggered by ice and rock collapses along the Himalayas is continuing to rise. Glaciers across the region are retreating, and glacial lakes are expanding, increasing the likelihood of disasters such as glacial lake outbursts and ice avalanches," Xu said in the interview on Aug. 28.

Xu didn't mention the cross-border early warning system, and he didn't say explicitly whether China had taken any preventive measures or issued any warning before the flood.

China expert Li Linyi noted that Xu's remarks echoed recommendations the Chengdu research team had already laid out a year earlier, effectively amounting to an implicit admission that the preventive measures previously proposed to authorities were never implemented.

"This is not simply an unforeseeable natural disaster," he said in a recent interview with The Epoch Times, "but the inevitable result of absent early warning, delayed decision-making, and systematically underestimated risk."

On Aug. 27, the South China Morning Post reported that Chinese scientists have had a cross-border early warning system with counterparts in Nepal since 2017 to monitor Himalayan glacial lake outburst floods, and that the system had reportedly issued timely alerts in past years that helped prevent casualties.

Yet despite this track record, the report did not clarify whether the system detected any anomalies or issued any alerts ahead of the Aug. 26 disaster this year.

Independent verification of such claims is difficult because under CCP rule, Tibet remains largely closed to foreign journalists, researchers, and diplomats.

Natural Disaster, or Man-Made?

The Gyirong Port is built in unstable geological terrain, according to Chinese state-run media platform Sohu. The Chengdu research report lays out in more detail the risks and hazards in the upstream regions.

By 2024, trade through Gyirong Port had already hit 4.25 billion yuan (roughly $590 million) - nearly 30 percent of all China-Nepal trade.

The disaster has drawn accusations that the CCP's focus on the economy and disregard for known risks turned a natural hazard into a man-made tragedy.

Ethan Tu, founder of Taiwan AI Labs, wrote on Facebook on Aug. 28, "The greatest crime any of us can make is to call a man-made disaster a natural one."

He referred to the CCP's building of the port complex right in the middle of the river, blocking water flow and causing the disaster.

Lin Ting-hui, former deputy secretary-general of the Taiwan Society of International Law, criticized the CCP for building dams, roads, and tunnels that have destroyed local ecological conditions and geological stability in Tibet and neighboring areas.

"On top of that, accelerating glacial melt means meltwater keeps seeping into loosened mountainsides - so when heavy rain hits, the resulting mudslides can end up far bigger and more destructive than they'd otherwise be," Lin said in a recent interview with The Epoch Times.

He blamed the CCP for building the entire port complex right on top of a riverbed, calling it a move that "defies nature."

Lin said that Gyirong has served as a vital route since the seventh and eighth centuries, once used by Tang dynasty envoys and Buddhist monks, and holds deep significance in Tibetan Buddhist history.

"In all those centuries, the area had never suffered a disaster on this scale. However, in recent years, flooding began recurring," Lin said in a recent interview with The Epoch Times.

"The CCP's atheism has led it to believe man can conquer nature. But people must instead respect nature, or nature will strike back."

Tang Bing, Chang Chun, and Rex Widerstrom contributed to this report.

https://www.zerohedge.com/weather/chinese-scientists-flagged-glacial-flood-danger-one-year-nepal-catastrophe

Hunter Biden used cushy Burisma gig to fund crack cocaine addiction

 Hunter Biden acknowledged in a new interview that his lucrative board appointments, including one at Ukrainian energy company Burisma, helped finance his crack cocaine addiction. 

“I never went broke,” Biden boasted on the “Dopey” podcast, after describing a two-month-long bender at the Chateau Marmont in Hollywood, Calif., where the former first son said he tried to “go out with a bang.” 

“Dopey” host Dave Manheim asked Biden how he was able to “scrape the money together” for the cocaine and prostitutes and private bungalows at the luxurious Chateau Marmont

“Well, I still had the residual. Like for instance, I still was on the board of Burisma,” Biden explained.  

A man wearing a black cap with a California Republic bear emblem and a black t-shirt sits with a microphone in front of him.
Hunter Biden reportedly made $50,000 per month to sit on Burisma’s board of directors.Dopey Podcast/Youtube
Biden earned up to $1 million per year ($50,000 per month) from 2014 to 2019 to serve on the Burisma board, despite having no relevant energy industry experience.

During Joe Biden’s presidency, Republican lawmakers probed the first son’s involvement with Burisma as part of a sprawling investigation into an alleged Biden family influence-peddling operation. 

As vice president, Joe Biden supported Ukraine’s natural gas industry after Hunter quietly joined Burisma in April 2014. Hunter’s infamous abandoned laptop also showed that his father met with a Burisma executive at a Washington, DC, dinner a year later. 

On the “Dopey” podcast, Hunter was adamant that he was qualified for the Burisma job and said he wasn’t “running some kind of international crime syndicate.” 

“What people don’t understand about Burisma is that I went on the board of Burisma because I had been on the board of about 14 other major national and international organizations,” he claimed. “I was chairman of the board of the UN World Food Program, which is the largest humanitarian organization in the world — we increased the budget when I was chairman from $1.8 billion to $2.6 billion when I was there.” 

Hunter Biden and his wife Melissa Cohen Biden depart a Presidential Citizens Medal ceremony.
Congressional Republicans probed Biden’s Burisma links as part of an investigation into an alleged Biden family influence-peddling operation.Bloomberg via Getty Images

Hunter went on and on and on about his cushy board gigs. 

“I was the vice chairman of the board of Amtrak, the national passenger rail system. I was chairman of the board of the Center for National Policy, the Truman National Security, you know, project, and on and on and on. And I was a professor at Georgetown in the School of Foreign Service in the Master’s program for four years, in one of the most popular classes at Georgetown, and and I was of counsel to Boies Schiller, which is one of the you know most preeminent law firms in the world — and so it wasn’t like, ‘Oh my God, he’s not qualified,’” Hunter argued. 

The former first son bragged that his plum Bursima post, in particular, was no problem to manage while in the throes of addiction. 

“I took that when my dad was vice president, and then for three years after I was still on the board, and the requirement of the board would be that I would show up for four meetings a year,” he explained. 

“Even when I was a crack addict and out of my mind, I could show up for four meetings a year.” 

Hunter agreed with Manheim that people can underestimate drug addicts, arguing that they “can do a lot of cool stuff.”

https://nypost.com/2026/08/31/us-news/hunter-biden-used-cushy-burisma-gig-to-feed-his-crack-cocaine-addiction/